ATE457741T1 - Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden - Google Patents

Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden

Info

Publication number
ATE457741T1
ATE457741T1 AT02804948T AT02804948T ATE457741T1 AT E457741 T1 ATE457741 T1 AT E457741T1 AT 02804948 T AT02804948 T AT 02804948T AT 02804948 T AT02804948 T AT 02804948T AT E457741 T1 ATE457741 T1 AT E457741T1
Authority
AT
Austria
Prior art keywords
therapeutic reagent
specific targeting
host
disease focus
enzymatic cleavable
Prior art date
Application number
AT02804948T
Other languages
English (en)
Inventor
B P Morgan
C L Harris
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0130104A external-priority patent/GB0130104D0/en
Priority claimed from GB0213619A external-priority patent/GB0213619D0/en
Application filed by Univ Cardiff filed Critical Univ Cardiff
Application granted granted Critical
Publication of ATE457741T1 publication Critical patent/ATE457741T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02804948T 2001-12-17 2002-11-27 Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden ATE457741T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0130104A GB0130104D0 (en) 2001-12-17 2001-12-17 Cleavable reagents for specific delivery to disease sites
GB0213619A GB0213619D0 (en) 2002-06-13 2002-06-13 Cleavable reagents for specific delivery to disease sites
PCT/GB2002/005371 WO2003051393A2 (en) 2001-12-17 2002-11-27 Enzymatic cleavable reagents for specific delivery to disease sites

Publications (1)

Publication Number Publication Date
ATE457741T1 true ATE457741T1 (de) 2010-03-15

Family

ID=26246877

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804948T ATE457741T1 (de) 2001-12-17 2002-11-27 Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden

Country Status (8)

Country Link
US (1) US20060246066A1 (de)
EP (1) EP1461086B1 (de)
JP (1) JP4342314B2 (de)
AT (1) ATE457741T1 (de)
AU (1) AU2002366303B2 (de)
CA (1) CA2470643C (de)
DE (1) DE60235408D1 (de)
WO (1) WO2003051393A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124097B2 (en) 2004-01-21 2012-02-28 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
JP2007099750A (ja) * 2005-02-25 2007-04-19 Hokkaido Univ 腫瘍組織で選択的に分解性を示す血中滞留性素子
DK2208737T3 (en) * 2007-05-03 2017-09-18 Lysomab Gmbh Complement factor H-derived short-consensus repeat antibody constructs
EP2190861A4 (de) 2007-08-22 2011-03-30 Univ California Aktivierbare bindende polypeptide und verfahren zu deren identifikation und anwendung
GB0820786D0 (en) * 2008-11-13 2008-12-24 Nordic Bioscience As Assessment of protein degradation by measurement of collagen fragments
CN106995495A (zh) * 2009-01-12 2017-08-01 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
JP5861223B2 (ja) * 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
IL210093A0 (en) 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
AU2013211824B2 (en) * 2012-01-27 2017-06-01 Gliknik Inc. Fusion proteins comprising IgG2 hinge domains
CN109053903B (zh) * 2018-09-12 2020-06-16 中国人民解放军沈阳军区总医院 一种重组人CREG-Fc融合蛋白的制备及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5658592A (en) * 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
JP2001505194A (ja) * 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー 分枝ペプチド・リンカー
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
AU4583601A (en) * 2000-03-15 2001-09-24 Du Pont Pharm Co Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

Also Published As

Publication number Publication date
JP2005516016A (ja) 2005-06-02
US20060246066A1 (en) 2006-11-02
AU2002366303B2 (en) 2007-09-20
JP4342314B2 (ja) 2009-10-14
WO2003051393A2 (en) 2003-06-26
CA2470643C (en) 2011-10-18
AU2002366303A1 (en) 2003-06-30
WO2003051393A3 (en) 2003-10-16
EP1461086A2 (de) 2004-09-29
DE60235408D1 (de) 2010-04-01
EP1461086B1 (de) 2010-02-17
CA2470643A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
DK1992695T3 (da) Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf
ATE457741T1 (de) Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
CY1107995T1 (el) ΑΝΑΣΤΟΛΗ ΔΡΑΣΤΙΚΟΤΗΤΑΣ p38 ΚΙΝΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΑΡΥΛ ΚΑΙ ΕΤEPΟΑΡΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΤEPΟΚΥΚΛΙΚΕΣ ΟΥΡΙΕΣ
BR0210471A (pt) Ligandos do receptor 5-ht e suas utilizações
BR0210839A (pt) Sistema de recombinação, método para remover uma sequência de dna do dna cromossÈmico de uma célula ou organismo eucarióticos, organismo, cultura de célula, órgão, tecido, parte ou material de propagação transgênico, e, uso de um organismo ou de uma cultura de célula, órgão, tecido, parte ou material de propagação transgênico
NO20020348L (no) Peptid acceptor ligeringsmetoder
AU7736300A (en) Therapeutic treatment of androgen receptor driven conditions
BRPI0507808A (pt) métodos de modular a atividade de citocina; reagentes relacionados
BRPI0507776A (pt) métodos de modular a atividade de citocina; reagentes relacionados
DK1053313T3 (da) Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
DE60333004D1 (de) Antikrebsmittel mit verotoxinvarianten
ATE534902T1 (de) Replikationsproteinn ciz1
WO2003087317A3 (en) Methods for targeting quadruplex dna
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
DE50009838D1 (de) Humanes antibiotisches protein
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
WO2002076280A3 (en) Methods and kits for determing a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
WO2003087840A3 (en) Protein involved in cancer
BR0204160A (pt) Composto ciclopaladado, composição e unidade de dosagem, seus usos, método para inibir a atividade de proteìnas e enzimas e método de tratamento de distúrbios ou doenças associadas às mesmas e método de modulação do sistema imunológico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties